TABLE 1.
All, n (%) | Preexisting ILS | p | ||
---|---|---|---|---|
Yes, n (%) | No, n (%) | |||
Patients | 195 | 40 | 155 | |
Age | ||||
Median (range) | 73 (44–95) | 77 (46–88) | 72 (44–95) | 0.0043 |
≥75 years | 87 (45) | 26 (65) | 61 (39) | |
Sex | 0.59 | |||
Male | 71 (36) | 16 (40) | 55 (35) | |
ECOG PS | 0.27 | |||
0–1 | 158 (81) | 30 (75) | 128 (83) | |
≥2 | 37 (19) | 10 (25) | 27 (17) | |
Smoking status | 0.28 | |||
Never‐smoker | 117 (60) | 21 (53) | 96 (62) | |
Current or former smoker | 78 (40) | 19 (47) | 59 (38) | |
EGFR mutation type | ||||
Major mutation | 78 (40) | 11 (28) | 67 (43) | |
Major + T790M | 113 (58) | 27 (68) | 86 (55) | |
Other | 4 (2.1) | 2 (5) | 2 (1.3) | |
EGFR‐TKI | 0.15 | |||
Naïve | 80 (41) | 12 (30) | 68 (44) | |
Treated | 115 (59) | 28 (70) | 87 (56) | |
Thoracic radiotherapy | 6 (3.1) | 4 (10) | 2 (1.3) | 0.017 |
Previous treatment with ICIs | 1 (0.51) | 0 (0.0) | 1 (0.65) | |
Preexisting ILS | ||||
Indeterminant ILA | 19 (48) | |||
ILA | 21 (53) |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group; performance status; EGFR, epidermal growth factor receptor: major mutation, exon 19 deletion and L858R mutation; ICIs, immune checkpoint inhibitor; ILA, interstitial lung abnormalities; ILS, interstitial lung abnormal shadow; TKI, tyrosine kinase inhibitor.